Studies suggest that DSIP exhibits strong potential within the realm of sleep research, with potential impacts like the better regulation of sleep cycles and thereby supporting improved physiological function.
Research suggests that as a result of these impacts, DSIP is a significant chemical in the fields of psychiatry and sleep.
DSIP Peptide: What is it?
Nine amino acids comprise the Delta Sleep-Inducing Peptide (DSIP) neuropeptide. Electric stimulation of the intraluminal thalamic region puts rabbits to sleep, and its isolation from their brains revealed that it is mostly generated in the central nervous system. The peptide's prospective function in controlling sleep patterns and enhancing sleep-related health has garnered interest because of its sleep-related production.
Investigations purport that since DSIP is a brain chemical, it may interact with receptors that regulate the sleep cycle. In particular, it may affect the central nervous system's alpha 1-adrenergic receptors, gamma-aminobutyric acid (GABA) receptors, and N methyl-D-aspartate (NMDA) receptors. Ultimately, this has been hypothesized to optimize the different phases of sleep and manipulate the architecture of sleep, particularly the very restorative slow-wave sleep (SWS), also called deep sleep or stage 3 sleep.
Findings imply that its potential for stress management and anxiety reduction may also affect sleep quality. Also, DSIP's potential has prompted researchers to investigate its potential uses in research:
- It may affect hormone levels
- It may alleviate distress hormone secretion
The mechanics and possible properties of DSIP require more investigation, but it has attracted the attention of researchers seeking to improve sleep quality and reduce stress.
DSIP Peptide potential
Researchers should note that further research is necessary to understand the effects and processes of this peptide completely. Research that is currently accessible suggests these may be some of the main properties of DSIP, as hypothesized by experimental investigations:
DSIP Peptide and sleep
Investigations purport that DSIP may theoretically increase sleep quality and promote rejuvenation by modulating the sleep-wake cycle, which helps induce sleep. Some of the most important studies suggesting the peptide's promise are as follows:
Results from deep slow-wave sleep (SWS) and non-rapid eye movement (NREM) sleep appeared to improve in rats given DSIP (Kastriuchenka et al., 2019). According to the study's authors, better sleep quality and general physiological function have been theorized to result from DSIP's potential to control sleep architecture.
Schneider-Helmert et al. (1981) studied the effects of intermediate-term presentation of DSIP on sleep and daytime performance in a group of fourteen research models with insomnia. Subjects received either DSIP or a placebo for seven nights in a row as part of the study's placebo-controlled design. Research models exposed to DSIP suggested a statistically significant increase in sleep quality, as measured by polysomnograms.
Additionally, the second research suggests that stage-4 sleep, or rapid eye movement (REM) sleep, may also benefit from DSIP when dreams occur. Rapid eye movement (REM) sleep may be crucial for processing and consolidating emotional memory.
DSIP Peptide and stress hormones
Some studies have suggested that DSIP may improve sleep quality and modify the organism's reaction to stress. One rabbit study purported that DSIP may ameliorate stress-related events, including extrasystoles, and decrease electrical instability of the heart under emotional stress. More study is required to assess DSIP's potential for stress reduction and mood improvement further.
DSIP Peptide, Withdrawal and the Brain
In addition to its potential for sleep start and architecture, DSIP may have practical effects on research models of addiction due to its interaction with opioid receptors. Two noteworthy experiments purporting these possible properties are shown below.
The agonistic action of DSIP on opiate receptors was the rationale for its presentation in research that included 107 research models of alcohol (n = 47) or opiate (n = 60) withdrawal symptoms. Results implied that DSIP may have impacted 87% of research models with alcohol withdrawal and 97% of opiate withdrawal models with their symptoms or eliminated them.
DSIP Peptide and pain
The possible analgesic effects of DSIP have been investigated in light of its potential on several biochemical and physiological parameters, as well as its interactions with opioid systems.
Research models of chronic pain, including migraines, vasomotor headaches, chronic tinnitus, and psychogenic pain episodes, were evaluated in pilot research to determine the potential of DSIP. As part of the research, DSIP was presented five days in a row, with further concentrations given every 48 to 72 hours. Out of the research models, 90% seemed to exhibit signs of much less discomfort. The occurrence of related depressive episodes also appeared to decrease significantly.
The antinociceptive potential of DSIP was examined in rats and mice. When DSIP was presented in mice's cerebrospinal fluid and brain circulation, the tail-pinch and hot-plate tests suggested a concentration-dependent decrease in pain sensitivity. It seems that DSIP may operate at a supraspinal level, perhaps affecting opioid receptors, as the opioid antagonist naloxone counteracted its antinociceptive effects and was not seen in morphine-tolerant rats.
Visit Core Peptides for more educational articles about peptides, what they are, how they work, and their potential uses and properties in research.
References
[i] Graf MV, Schoenenberger GA. Delta sleep-inducing peptide modulates the stimulation of rat pineal Nacetyltransferase activity by involving the alpha 1- adrenergic receptor. J Neurochem. 1987 Apr;48(4):1252-7. doi: 10.1111/j.1471- 4159.1987.tb05654.x. PMID: 3029331.
[ii] Tukhovskaya EA, Ismailova AM, Shaykhutdinova ER, Slashcheva GA, Prudchenko IA, Mikhaleva II, Khokhlova ON, Murashev AN, Ivanov VT. Delta Sleep-Inducing Peptide Recovers Motor Function in SD Rats after Focal Stroke. Molecules. 2021 Aug 26;26(17):5173. doi: 10.3390/molecules26175173. PMID: 34500605; PMCID: PMC8434407.
[iii] Graf, M. V., & Kastin, A. J. (1986). Delta-sleepinducing peptide (DSIP): an update. Peptides, 7(6), 1165–1187. https://doi.org/10.1016/0196- 9781(86)90148-8
[iv] Schneider-Helmert D. (1984). DSIP in insomnia. European neurology, 23(5), 358–363. https://doi.org/10.1159/000115714
[v] K Nakagaki, S Ebihara, S Usui, Y Honda, Y Takahashi. Sleep-promoting effect following intracerebroventricular injection of a phosphorylated analogue of delta sleep-inducing peptide (DSIP-P) in rats. Neuroscience Letter1988 Aug 31;91(2):160-4.
[vi] D Schneider-Helmert, G A Schoenenberger.The influence of synthetic DSIP (delta-sleep-inducing peptide) on disturbed human sleep. Experientia 1981;37(9):913-7
[vii] Arkhangel'skaia MI, Zviagintseva MA. Vliianie peptida del'ta-sna na élektricheskuiu nestabil'nost' serdtsa pri émotsional'nom stresse [Effect of deltasleep inducing peptide on electrical instability of the heart in emotional stress]. Patol Fiziol Eksp Ter. 1989 Mar-Apr;(2):45-9. Russian. PMID: 2755725.
[viii] Dick P, Costa C, Fayolle K, Grandjean ME, Khoshbeen A, Tissot R. DSIP in the treatment of withdrawal syndromes from alcohol and opiates. Eur Neurol. 1984;23(5):364-71. doi: 10.1159/000115715. PMID: 6548969.
[ix] Soyka M, Rothenhaeusler HB. Delta sleep-inducing peptide in opioid detoxification. Am J Psychiatry. 1997 May;154(5):714-5. doi: 10.1176/ajp.154.5.714b. PMID: 9137140.
[x] Larbig W, Gerber WD, Kluck M, Schoenenberger GA. Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes. A clinical pilot study. Eur Neurol. 1984;23(5):372-85. doi: 10.1159/000115716. PMID: 6548970.